Investors & Media Contact Us Linkedin Twitter Who We Are Focus Areas Pipeline Patients Careers Focus Areas Too many loved ones live with uncertainty. Let’s find answers. We focus on patients with rare tumors, hematological cancers and biomarker-defined metastatic solid tumors. Because the need is great, we are digging deep into the science of our lead product candidates – nirogacestat and mirdametinib – to unlock their full potential while simultaneously developing other promising molecules. As part of our approach, we are actively pursuing new licensing and partnership opportunities with other innovators to help advance promising science as efficiently as possible so people living with devastating cancers can live better. Let’s get novel for patients living with rare tumors Our lead program, nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) in Phase 3 development for adult patients with desmoid tumors. These are rare, aggressive soft-tissue tumors characterized by locally invasive growth, significant morbidity, and a high rate of recurrence. We are also developing mirdametinib, our MEK inhibitor, for patients with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), which are peripheral nerve sheath tumors that cause severe disfigurement, pain and functional impairment. NF1-PN can also become malignant over time. Learn more Linkedin Twitter Who We Are Leadership & Board Mission & Values Partners & Collaborators Focus Areas Rare Oncology BCMA Combinations in Multiple Myeloma Biomarker-Defined Metastatic Solid Tumors Pipeline Nirogacestat Mirdametinib Clinical Trials Investigator-Initiated Research Careers View Opportunities Patients Desmoid Tumors NF1-PN Expanded Access Contact Investors & Media Press Releases Events & Presentations Corporate Governance Financial Information Stock Information Investor Resources © 2021 SpringWorks Therapeutics. All rights reserved. Privacy Policy Terms of Use By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookies Settings Reject All Accept All Cookies